What thymia does

thymia (legal entity THYMIA LIMITED, England and Wales) is a London-based voice biomarker AI company founded in 2020 that extracts clinical and wellbeing signals from natural human speech. Its core technology analyses acoustic features (pitch variation, speech rate, pauses, vocal tremor, loudness), linguistic patterns, and temporal dynamics using proprietary "Neural Morphemes™" — fundamental speech units the company claims carry biological meaning beyond words. The product portfolio comprises Helios (non-clinical wellbeing and safety monitoring), Apollo Clinical (a UKCA Class I regulated medical device for depression and anxiety assessment covering all DSM-V criteria), Sentinel and Lyra (real-time voice-agent safety monitoring that streams audio without storing recordings), and a REST API plus Activity Plugin for enterprise integration. From 15 seconds of speech, thymia's models claim to extract 30+ biomarkers at 85%+ accuracy across 11 languages, validated against gold-standard clinical benchmarks on a dataset of 75,000+ unique voices.

The company monetises via enterprise API subscriptions and Activity Plugin licensing, both priced by configurable "Wellness Check" packages on annual billing with overage mechanics and whitelabelling options; pricing is quote-based and not publicly disclosed. Go-to-market is API-first, targeting four primary verticals: healthcare systems (clinical decision support, remote patient monitoring, mental health triage), automotive OEMs (driver fatigue detection ahead of an EU July 2026 mandate), voice AI agent platforms (real-time distress detection during AI conversations), and safety-critical industries (North American first-responder agencies). Distribution is anchored by two April 2026 strategic partnerships — with Agora (real-time voice infrastructure) and Speechmatics (medical-grade ASR) — alongside direct enterprise sales and developer-led adoption via docs.thymia.ai.

As of the latest data, thymia has raised approximately USD 5.6M in total funding (USD 1.1M pre-seed in 2021, ~USD 3.07M seed in July 2023 led by Kodori AG, ~USD 1.4M Crowdcube extension in July 2023) and operates with 11–50 employees. It holds ISO 27001, ISO 13485, HIPAA, GDPR, Cyber Essentials, NHS Digital Toolkit, and Crown Commercial Service certifications, and is led by CEO and co-founder Emilia Molimpakis alongside CTO and co-founder Stefano Goria.

Name

thymia

Legal name

THYMIA LIMITED

Website

https://thymia.ai

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

thymia is a London-based voice biomarker AI company that extracts 30+ clinical and wellbeing signals — including depression, anxiety, fatigue, and cardiovascular risk — from 15 seconds of natural speech, selling API access to healthcare systems, automotive OEMs, voice AI platforms, and safety-critical industries.

Ownership category

akta.pro rank

Product category

Voice Biomarker AI / Healthcare Speech Analytics

akta.pro primary industry

SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)

akta.pro secondary industries

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)

Keywords

• Voice biomarker platform
• Mental health assessment
• Clinical speech analysis
• Voice AI infrastructure
• Health detection API

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. API Access Subscription: Customers purchase access to thymia's media API and activity plugin. Fees are determined by the number of Wellness Checks selected. The platform offers configurable data deletion options and supports whitelabelling for enterprise customers.
2. Activity Plugin Licensing: Customers purchase access via thymia's activity plugin which may be whitelabelled or non-whitelabelled. Whitelabelling allows customers to use their own branding. Usage above agreed package limits results in overage billing.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

thymia is a foundational voice biomarker AI platform that extracts 30+ health and wellbeing signals (depression, anxiety, fatigue, stress, cardiovascular risk, respiratory indicators, metabolic markers) from just 15 seconds of natural speech in real time. The company exposes its technology through a REST API and offers three core models: Helios for non-clinical wellbeing and safety monitoring, Apollo Clinical as a UKCA Class I regulated medical device for clinical-grade depression and anxiety assessment, and Sentinel/Lyra for real-time voice AI safety monitoring during live conversations.

Product overview

thymia is a foundational voice biomarker platform offering a modular product portfolio centered on extracting health signals from speech. The core offering includes three specialized models: Helios for wellbeing and safety monitoring, Apollo Clinical for clinical-grade depression and anxiety assessment, and Sentinel/Lyra for real-time voice AI monitoring. These are accessible via the thymia REST API, the thymia Activity Plugin for guided recording capture, and the Speechmatics-thymia Joint Platform for combined speech-to-text and biomarker intelligence. The platform processes voice at 15-second intervals, analyzing neural morphemes across acoustic, linguistic, and temporal patterns to generate 30+ clinical and wellbeing biomarker scores.

Differentiator

Problem solved

Functional benefit

Brands

• Helios: Wellbeing and safety monitoring model - detects distress, stress, fatigue, low self-esteem, and burnout in real time for healthcare, pharma, and safety-critical industries.
• Apollo Clinical
• Sentinel

Products and services

• Helios Wellbeing and safety monitoring model detecting distress, stress, fatigue, low self-esteem, and burnout in real time across human and voice agent interactions. Designed for non-clinical settings including healthcare, pharma, and safety-critical industries.
• Apollo Clinical Clinical-grade voice-based depression and anxiety assessment covering all DSM-V criteria with disorder-level probability scores and granular symptom breakdowns. UKCA Class I regulated medical device intended for qualified healthcare professionals only. Requires two audio recordings with 15-second minimum per recording.
• Sentinel Real-time voice safety and wellbeing monitoring layer for live voice AI applications. Streams audio from existing voice stack and returns biomarker signals in real time during conversations without storing recordings. Designed for AI agents and voice platforms requiring immediate health and safety intelligence.
• Lyra Voice agent safety and monitoring product providing real-time biomarker extraction during live voice conversations. Supports custom organisation policies, demographics endpoint integration, speech progress events, and optional psyche biomarker analysis.
• thymia API REST API providing programmatic access to Helios, Apollo, and Sentinel models. Enables asynchronous voice recording submission with polling for results. Supports multiple audio formats and 11 language codes. Authentication via API key.
• thymia Activity Plugin Activity-based recording capture module that hosts activities (such as read-aloud tasks or mood question responses) to collect voice recordings for model analysis. Supports whitelabelling for customer branding.
• Speechmatics-thymia Joint Platform Combined platform integrating Speechmatics' medical-grade speech-to-text with thymia's clinical-grade voice biomarker intelligence. Identifies 30+ health signals from 15 seconds of natural speech at over 85% accuracy.

Quantifiable outcome

• 85%+ accuracy against gold standards for health detection
• +5 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• AgoracoreTechnology or Integration · 24 April 2026Strategic partnership integrating thymia's clinically validated voice analysis technology into Agora's real-time engagement infrastructure. The collaboration enables detection of mental and physical health indicators including depression, anxiety, stress, and cardiovascular risk by analyzing 15 seconds of speech during live voice interactions. Targets healthcare, automotive, workplace wellness, and education sectors at enterprise scale.
• SpeechmaticscoreTechnology or Integration · 16 April 2026Partnership combining medical-grade speech-to-text (Speechmatics) with clinical-grade voice biomarker intelligence (thymia). The joint platform identifies 30+ health signals from 15 seconds of natural speech including stress, fatigue, depression/anxiety symptoms, type 2 diabetes, and driver impairment, then acts on them in real time. Delivered through a single integration returning health signals alongside standard transcription at over 85% accuracy.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Sonde Health: Sonde Health builds a voice biomarker platform that detects mental and physical health conditions from short voice samples, including depression, anxiety, and respiratory conditions. It is the closest direct competitor to thymia in clinical-grade voice biomarker SaaS for enterprise healthcare and life sciences.
• Ellipsis Health: Ellipsis Health uses AI vocal biomarker analysis to detect anxiety and depression in patient conversations and is deployed across US health systems. It competes head-to-head with thymia's Apollo product for healthcare-system mental-health screening contracts.
• Kintsugi: Kintsugi offers voice-based mental health screening for depression and anxiety via a short voice sample, targeting payers, providers, and digital health platforms. It is a direct comparable in product, intended use, and customer profile.
• Winterlight Labs: Winterlight Labs analyses speech and language patterns to detect cognitive and mental health conditions, primarily for clinical trials and pharmaceutical research. It overlaps with thymia on the underlying speech biomarker technology and clinical evidence generation, though it focuses on pharma rather than real-time enterprise deployment.

Broad incumbents

• Hume AI: Hume AI provides a voice and expression AI platform measuring emotion, wellbeing, and tone in real time for developers and enterprises. It competes in the same voice-emotion AI category as thymia but offers broader emotion/wellbeing APIs rather than regulated clinical biomarkers.
• Cogito: Cogito analyses vocal cues in real time to coach call-centre agents on empathy, energy, and engagement. It is an established incumbent in voice-emotion AI for enterprise call centres, overlapping with thymia's Sentinel/Lyra use case but targeting CX rather than health.
• Affectiva (Smart Eye): Affectiva, now part of Smart Eye, provides emotion-detection AI from face and voice for automotive and media applications. It is a broader incumbent in driver monitoring and emotion AI, overlapping with thymia's automotive use case but from a multi-modal, larger-platform perspective.

Emerging players

• Behavioral Signals: Behavioral Signals applies emotion and sentiment analysis to voice in call-centre and conversational AI contexts. It is an emerging player in the same voice-emotion AI infrastructure category as thymia but is more focused on customer-experience analytics than regulated health biomarkers.
• Modulate: Modulate builds voice AI for real-time toxicity detection and speaker profiling in online communities and gaming. It is an adjacent emerging player in voice-emotion/character AI, sharing infrastructure-level voice intelligence customers with thymia but with a different application focus.
• VoiceSense: VoiceSense offers vocal biomarkers predicting behavioural and wellbeing traits for insurance, finance, and healthcare. It is an emerging peer in the predictive-voice-analytics space, with overlapping applicability to health and risk scoring from speech.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about thymia